Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.4760
-0.0131 (-2.68%)
At close: Oct 2, 2026, 4:00 PM EDT
0.4748
-0.0012 (-0.25%)
After-hours: Oct 2, 2026, 7:37 PM EDT
Pasithea Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
15.91M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 15.06K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 13.19M |
| Dyadic International | 3.80M |
| SeaStar Medical Holding | 1.71M |
| Allarity Therapeutics | 345.00K |
| Kiora Pharmaceuticals | 20.00K |
| BioCardia | 3.00K |
KTTA News
- 18 days ago - Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference - GlobeNewsWire
- 23 days ago - Pasithea Therapeutics Transcript: AGM 2026 - Transcripts
- 23 days ago - Pasithea Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences - GlobeNewsWire
- 7 weeks ago - Pasithea Therapeutics Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Pasithea Therapeutics Slides: Corporate presentation - Filings
- 1 month ago - Pasithea Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Pasithea Therapeutics Proxy statement: Proxy filing - Filings